WO2005075469A1 - Acides thiazolyl-hydroxamiques, acides thiadiazolyl-hydroxamiques et leur utilisation pour traiter des maladies associees a une activite enzymatique histone deacetylase - Google Patents

Acides thiazolyl-hydroxamiques, acides thiadiazolyl-hydroxamiques et leur utilisation pour traiter des maladies associees a une activite enzymatique histone deacetylase Download PDF

Info

Publication number
WO2005075469A1
WO2005075469A1 PCT/GB2005/000282 GB2005000282W WO2005075469A1 WO 2005075469 A1 WO2005075469 A1 WO 2005075469A1 GB 2005000282 W GB2005000282 W GB 2005000282W WO 2005075469 A1 WO2005075469 A1 WO 2005075469A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
heteroaryl
aryl
disease
cycloalkyl
Prior art date
Application number
PCT/GB2005/000282
Other languages
English (en)
Inventor
Walter Bordogna
Jonathan Mark Sutton
George Hynd
Hazel Joan Dyke
Stephen Price
Neil Victor Harris
Mathew Iain Andrew Gill
Original Assignee
Argenta Discovery Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenta Discovery Limited filed Critical Argenta Discovery Limited
Publication of WO2005075469A1 publication Critical patent/WO2005075469A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • This invention relates to substituted thiazolyl-hydroxamic acids and thiadiazolyl- hydroxamic acids, their preparation and pharmaceutical compositions containing these compounds for treating diseases associated with histone deacetylase enzymatic activity.
  • DNA is tightly associated with histones to form a compact complex called chromatin.
  • the histones generally highly conserved across eukaryotic species, constitute a family of proteins which are rich in basic amino acids that contact the phosphate groups of DNA.
  • H2A, H2B, H3 and H4 There are different types of histones, including HI, H2A, H2B, H3 and H4.
  • Approximately 146 base pairs of DNA wrap around a histone core to make up a nucleosome particle, the repeating structural motif of chromatin.
  • Histone deacetylases are part of transcriptional corepressor complexes and play key roles in regulating chromatin structure.
  • Three different classes of human HDACs have been defined based on their homology to HDACs found in Saccharomyces cerevisiae.
  • Class I HDACs HDAC1, 2, 3, and 8 are related to the yeast transcriptional regulator RPD3.
  • Class II HDACs HDAC4, 5, 6, 1, 9, and 10 are similar to HDAl, another deacetylase in yeast.
  • Class III HDACs are related to the yeast silencing protein SIR2 and are dependent on NAD for enzymatic activity.
  • HDAC histone deacetylase
  • HATs histone acetyltransferases
  • histone deacetylases have been shown to regulate the activity of non-histone proteins through the modification of their acetylation level.
  • steroid receptors such as estrogen and androgen receptors [Wang et al, J. Biol. Chem., 276:18375-83 (2001), Gaughan et al, J. Biol. Chem., 277: 25904-13 (2002)] transcription factors such as p53, E2F and myoD [Luo et al, Nature, 408:377-381 (2000); Ito et al, EMBO J, 19:1176-1179 (2001); Sartorelli et al, Mol. Cell, 4:725-734 (1999)], and cytoplasmic proteins such as ⁇ - tubulin [Hubbert et al, Nature, 417:455-458 (2002)].
  • HDAC HDAC-like oxidative deficiency oxidative deficiency oxidative deficiency oxidative deficiency oxidative deficiency oxidative deficiency oxidative deficiency oxidative deficiency oxidative deficiency oxidative deficiency oxidative deficiency oxidative deficiency oxidative deficiency oxidative deficiency oxidative deficiency Yoshida and Beppu, Exper. Cell Res. , 177:122-131 (1988)]; and (iii) chlamydocin. Synthetic inhibitors include suberoyl anilide hydroxamic acid [Richon et al, Proc. Natl. Acad. Sci. USA, 95: 3003-3007 (1998)] and phenylbutyrate [Johnstone R ⁇ Nat. Rev. Drug Discov., 1:287-299 (2002)].
  • Trichostatin A has been shown to cause arrest of rat fibroblasts at both G] and G phases of the cell cycle, implicating HDAC in cell cycle regulation [Yoshida and Beppu, Exper. Cell Res., 177:122-131 (1988)].
  • Trichostatin A and suberoyl anilide hydroxamic acid have been shown to inhibit cell growth, induce terminal differentiation and prevent the formation of tumors in mice [Johnstone RW Nat. Rev. Drug Discov., 1:287-299 (2002)].
  • Trapoxin, trichostatin, and depudecin have been used to study gene regulation by HDAC- mediated chromatin remodeling [Christian A. Hassig, Stuart L. Schreiber, Curr. Opinion in Chem.
  • the present invention provides compounds of formula (I):
  • A represents optionally substituted monocyclic heteroaryl or phenyl
  • B represents optionally substituted heteroaryl, aryl, aryl-fused-heterocycloalkyl, heteroaryl-fused-cycloalkyl, heteroaryl-fused-heterocycloalkyl or aryl-fused-cycloalkyl, or B represents H when L represents a single bond;
  • L represents a single bond, alkylene, (CH 2 ) n X(CH 2 ) m, (CH 2 ) n X(CH 2 ) p Y(CH 2 ) m ;
  • Q represents N or CR 2 ;
  • T represents N or CR , provided that Q and T do not both represent CR simultaneously;
  • X represents -O-, -NR 3 -, -CO-, -SO 2 -, -NR 3 CO-, -NR 3 SO 2 -, -CONR 3 -, -SO 2 NR 3 -, N ⁇ CONR 1 -;
  • Y represents -NR 3 - or -O-;
  • R 1 represents H or alkyl
  • R represents hydrogen, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, CN;
  • R 3 represents H, alkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkylalkyl, or alkyl substituted by -OR 4 , -NR R 6 , -NR 6 COR 7 , -NR 6 SO 2 R 7 , -CONR 5 R 6 or -SO 2 NR 5 R 6 ;
  • R 4 represents H, alkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl or cycloalkyl;
  • R 5 represents H or alkyl
  • R 6 represents H, alkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl or cycloalkyl
  • NR R represents a cyclic amine
  • R 7 represents alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl;
  • a second aspect of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I) or an N-oxide, pharmaceutically acceptable salt, solvate or prodrug thereof, in admixture with a pharmaceutically acceptable carrier or excipient.
  • a third aspect of the invention is a compound of formula (I) or an N-oxide, pharmaceutically acceptable salt, solvate or prodrug thereof for use in therapy.
  • a fourth aspect of the invention is the use of a compound of formula (I), or an N-oxide, pharmaceutically acceptable salt, solvate or prodrug thereof, in the manufacture of a medicament for the treatment of a disease in which inhibition of histone deacetylase can prevent, inhibit or ameliorate the pathology and/or symptomatology of the disease.
  • a fifth aspect of the invention is a method for treating a disease in a patient in which inhibition of histone deacetylase can prevent, inhibit or ameliorate the pathology and/or symptomatology of the disease, which method comprises administering to the patient a therapeutically effective amount of compound of formula (I) or an N-oxide, pharmaceutically acceptable salt, solvate or prodrug thereof.
  • a sixth aspect of the invention is a method of inhibiting histone deacetylase in a cell, comprising contacting a cell in which inhibition of histone deacetylase is desired with a compound of formula (I) or an N-oxide, pharmaceutically acceptable salt, solvate or prodrug thereof.
  • a seventh aspect of the invention is a method of preparing a compound of formula (I) or an N-oxide, pharmaceutically acceptable salt, solvate or prodrug thereof.
  • An eighth aspect of the invention is a method of making a pharmaceutical composition
  • a pharmaceutical composition comprising combining a compound of formula (I), or an N-oxide, pharmaceutically acceptable salt, solvate or prodrug thereof, with a pharmaceutically acceptable carrier or excipient.
  • Histone deacetylase and "HDAC” are intended to refer to any one of a family of enzymes that remove acetyl groups from lysine residues of proteins including, but not limited to, histones, transcription factors, steroid receptors and tubulin. Unless otherwise indicated the term histone is meant to refer to any histone protein, including HI, H2A, H2B, H3, H4 and H5 from any species.
  • the histone deacetylase is a human HDAC, including, but not limited to, HDAC-1, HDAC-2, HDAC- 3, HDAC-4, HDAC-5, HDAC-6, HDAC-7, HDAC-8, HDAC-9, and HDAC-10.
  • the histone deacetylase is derived from a protozoal or fungal source.
  • Patient includes both human and other mammals.
  • acyl means a -CO-alkyl group in which the alkyl group is as described herein.
  • exemplary acyl groups include -COCH 3 and -COCH(CH 3 ) 2 .
  • acylamino means a -NR-acyl group in which R and acyl are as described herein.
  • exemplary acylamino groups include -NHCOCH 3 and -N(CH 3 )COCH 3 .
  • Alkoxy and “alkyloxy” means an -O-alkyl group in which alkyl is as defined below.
  • exemplary alkoxy groups include methoxy and ethoxy.
  • Alkoxycarbonyl means a -COO-alkyl group in which alkyl is as defined below.
  • exemplary alkoxycarbonyl groups include methoxycarbonyl and ethoxycarbonyl.
  • Alkyl as a group or part of a group refers to a straight or branched chain saturated hydrocarbon group having from 1 to 12, preferably 1 to 6, carbon atoms, in the chain.
  • exemplary alkyl groups include methyl, ethyl, 1-propyl and 2-propyl.
  • Alkylamino means a -NH-alkyl group in which alkyl is as defined above.
  • exemplary alkylamino groups include methylamino and ethylamino.
  • Alkylene means an -alkyl- group in which alkyl is as defined previously.
  • exemplary alkylene groups include -CH 2 -, -(CH 2 ) 2 and -C(CH 3 )HCH 2 -.
  • Alkylsufinyl means a -SO-alkyl group in which alkyl is as defined above.
  • exemplary alkylsulfinyl groups include methylsulfinyl and ethylsulfinyl.
  • Alkylsufonyl means a -SO2 ⁇ alkyl group in which alkyl is as defined above.
  • Exemplary alkylsulfonyl groups include methylsulfonyl and ethylsulfonyl.
  • Alkylthio means a -S-alkyl group in which alkyl is as defined above.
  • exemplary alkylthio groups include methylthio and ethylthio.
  • aminoacyl means a -CO-NRR group in which R is as herein described.
  • exemplary aminoacyl groups include -CONH 2 and -CONHCH 3 .
  • Aminoalkyl means an alkyl-NH 2 group in which alkyl is as previously described.
  • exemplary aminoalkyl groups include -CH NH 2 .
  • aminosulfonyl means a -SO 2 -NRR group in which R is as herein described.
  • exemplary aminosulfonyl groups include -SO NH and -SO 2 NHCH 3 .
  • Aryl as a group or part of a group denotes an optionally substituted monocyclic or multicyclic aromatic carbocyclic moiety of from 6 to 14 carbon atoms, preferably from 6 to 10 carbon atoms, such as phenyl or naphthyl, and in one embodiment preferably phenyl.
  • the aryl group may be substituted by one or more substituent groups.
  • Arylalkyl means an aryl-alkyl- group in which the aryl and alkyl moieties are as previously described. Preferred arylalkyl groups contain a Cj_4 alkyl moiety. Exemplary arylalkyl groups include benzyl, phenethyl and naphthlenemethyl.
  • Arylalkyloxy means an aryl-alkyloxy- group in which the aryl and alkyloxy moieties are as previously described. Preferred arylalkyloxy groups contain a C j _4 alkyl moiety.
  • Exemplary arylalkyl groups include benzyloxy.
  • Aryl-fused-cycloalkyr' means a monocyclic aryl ring, such as phenyl, fused to a cycloalkyl group, in which the aryl and cycloalkyl are as described herein.
  • Exemplary aryl- fused-cycloalkyl groups include tetrahydronaphthyl and indanyl.
  • the aryl and cycloalkyl rings may each be sustitued by one or more substituent groups.
  • the aryl-fused-cycloalkyl group may be attached to the remainder of the compound of formula (I) by any available carbon atom.
  • Aryl-fused-heterocycloalkyl means a monocyclic aryl ring, such as phenyl, fused to a heterocycloalkyl group, in which the aryl and heterocycloalkyl are as described herein.
  • Exemplary aryl-fused-heterocycloalkyl groups include tetrahydroquinolinyl, indolinyl, benzodioxinyl, benxodioxolyl, dihydrobenzofuranyl and isoindolonyl.
  • the aryl and heterocycloalkyl rings may each be sustitued by one or more substituent groups.
  • the aryl- fused-heterocycloalkyl group may be attached to the remainder of the compound of formula (I) by any available carbon or nitrogen atom.
  • Aryloxy means an -O-aryl group in which aryl is described above.
  • Exemplary aryloxy groups include phenoxy.
  • Cyclic amine means an optionally substituted 3 to 8 membered monocyclic cycloalkyl ring system where one of the ring carbon atoms is replaced by nitrogen, and which may optionally contain an additional heteroatom selected from O, S or NR (where R is as described herein).
  • Exemplary cyclic amines include pyrrolidine, piperidine, morpholine, piperazine and N-methylpiperazine.
  • the cyclic amine group may be substituted by one or more substituent groups.
  • Cycloalkyl means an optionally substituted saturated monocyclic or bicyclic ring system of from 3 to 12 carbon atoms, preferably from 3 to 8 carbon atoms, and more preferably from 3 to 6 carbon atoms.
  • Exemplary monocyclic cycloalkyl rings include cyclopropyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • the cycloalkyl group may be substituted by one or more substituent groups.
  • Cycloalkylalkyl means a cycloalkyl-alkyl- group in which the cycloalkyl and alkyl moieties are as previously described.
  • Exemplary monocyclic cycloalkylalkyl groups include cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl and cycloheptylmethyl.
  • Dialkylamino means a - ⁇ (alkyl)2 group in which alkyl is as defined above.
  • exemplary dialkylamino groups include dimethylamino and diethylamino.
  • Halo or “halogen” means fluoro, chloro, bromo, or iodo. Preferred are fluoro or chloro.
  • Haloalkoxy means an -O-alkyl group in which the alkyl is substituted by one or more halogen atoms.
  • exemplary haloalkyl groups include trifluoromethoxy and difluoromethoxy.
  • Haloalkyl means an alkyl group which is substituted by one or more halo atoms.
  • exemplary haloalkyl groups include trifluoromethyl.
  • Heteroaryl as a group or part of a group denotes an optionally substituted aromatic monocyclic or multicyclic organic moiety of from 5 to 14 ring atoms, preferably from 5 to 10 ring atoms, in which one or more of the ring atoms is/are element(s) other than carbon, for example nitrogen, oxygen or sulfur.
  • Examples of such groups include benzimidazolyl, benzoxazolyl, benzothiazolyl, benzofuranyl, benzothienyl, furyl, imidazolyl, indolyl, indolizinyl, isoxazolyl, isoquinolinyl, isothiazolyl, oxazolyl, oxadiazolyl, pyrazinyl, pyridazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, tetrazolyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl and triazolyi groups.
  • the heteroaryl group may be substituted by one or more substituent groups.
  • the heteroaryl group may be attached to the remainder of the compound of formula (I) by any available carbon or nitrogen atom.
  • Heteroarylalkyl means a heteroaryl-alkyl- group in which the heteroaryl and alkyl moieties are as previously described. Preferred heteroarylalkyl groups contain a lower alkyl moiety. Exemplary heteroarylalkyl groups include pyridylmethyl.
  • Heteroarylalkyloxy means a heteroaryl-alkyloxy- group in which the heteroaryl and alkyloxy moieties are as previously described. Preferred heteroarylalkyloxy groups contain a lower alkyl moiety. Exemplary heteroarylalkyloxy groups include pyridylmethyloxy.
  • Heteroaryloxy means a heteroaryloxy- group in which the heteroaryl is as previously described.
  • Exemplary heteroaryloxy groups include pyridyloxy.
  • Heteroaryl-fused-cycloalkyl means a monocyclic heteroaryl group, such as pyridyl or furanyl, fused to a cycloalkyl group, in which heteroaryl and cycloalkyl are as previously described.
  • Exemplary heteroaryl-fused-cycloalkyl groups include tetrahydroquinolinyl and tetrahydrobenzofuranyl.
  • the heteroaryl and cycloalkyl rings may each be sustitued by one or more substituent groups.
  • the heteroaryl-fused-cycloalkyl group may be attached to the remainder of the compound of formula (I) by any available carbon or nitrogen atom.
  • Heteroaryl-fused-heterocycloalkyl means a monocyclic heteroaryl group, such as pyridyl or furanyl, fused to a heterocycloalkyl group, in which heteroaryl and heterocycloalkyl are as previously described.
  • Exemplary heteroaryl-fused-heterocycloalkyl groups include dihydrodioxinopyridinyl, dihydropyrrolopyridinyl, dihydrofuranopyridinyl and dioxolopyridinyl.
  • the heteroaryl and heterocycloalkyl rings may each be sustitued by one or more substituents groups.
  • the heteroaryl-fused-heterocycloalkyl group may be attached to the remainder of the compound of formula (I) by any available carbon or nitrogen atom.
  • Heterocycloalkyl means: (i) an optionally substituted cycloalkyl group of from 4 to 8 ring members which contains one or more heteroatoms selected from O, S or NR; (ii) a cycloalkyl group of from 4 to 8 ring members which contains CONR and CONRCO (examples of such groups include succinimidyl and 2-oxopyrrolidinyl).
  • the heterocycloalkyl group may be substituted by one or more substituent groups.
  • the heterocycloalkyl group may be attached to the remainder of the compound of formula (I) by any available carbon or nitrogen atom.
  • Heterocycloalkylalkyl means a heterocycloalkyl-alkyl- group in which the heterocycloalkyl and alkyl moieties are as previously described.
  • “Lower alkyl” as a group means unless otherwise specified, an aliphatic hydrocarbon group which may be straight or branched having 1 to 4 carbon atoms in the chain, i.e. methyl, ethyl, propyl ("propyl or 'propyl) or butyl ("butyl, 'butyl or l butyl).
  • R means hydrogen, alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroarylalkyl, heteroaryl or aryl.
  • Sulfonyl means a -SO 2 -alkyl group in which alkyl is as described herein. Exemplary sulfonyl groups include methanesulfonyl.
  • “Sulfonylamino” means a -NR-sulfonyl group in which R and sulfonyl are as described herein.
  • Exemplary sulfonylamino groups include -NHSO CH 3 .
  • “Pharmaceutically acceptable salt” means a physiologically or toxicologically tolerable salt and include, when appropriate, pharmaceutically acceptable base addition salts and pharmaceutically acceptable acid addition salts.
  • pharmaceutically acceptable base addition salts that may be formed include sodium, potassium, calcium, magnesium and ammonium salts, or salts with organic amines, such as, diethylamine, N-methyl-glucamine, diethanolamine or amino acids (e.g.
  • a compound of the invention contains a basic group, such as an amino group
  • pharmaceutically acceptable acid addition salts that may be formed include hydrochlorides, hydrobromides, phosphates, acetates, citrates, lactates, tartrates, malonates, methanesulphonates and the like.
  • Prodrug means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis, reduction or oxidation) to a compound of formula (I).
  • metabolic means e.g. by hydrolysis, reduction or oxidation
  • an ester prodrug of a compound of formula (I) containing a hydroxy group may be convertible by hydrolysis in vivo to the parent molecule.
  • Suitable esters of compounds of formula (I) containing a hydroxy group are for example acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis- ⁇ -hydroxynaphthoates, gentisates, isethionates, di- j P-toluoyltartrates, methanesulphonates, ethanesulphonates, benzenesulphonates, p-toluenesulphonates, cyclohexylsulphamates and quinates.
  • ester prodrug of a compound of formula (I) containing a carboxy group may be convertible by hydrolysis in vivo to the parent molecule [Examples of ester prodrugs are those described by F. J. Leinweber, Drug Metab. Res., 18:379 (1987)]. "Saturated” pertains to compounds and/or groups which do not have any carbon-carbon double bonds or carbon-carbon triple bonds.
  • cyclic groups referred to above namely, aryl, heteroaryl, cycloalkyl, aryl-fused- cycloalkyl, heteroaryl-fused-cycloalkyl, heterocycloalkyl, aryl-fused-heterocycloalkyl, heteroaryl-fused-heterocycloalkyl and cyclic amine may be substituted by one or more substituent groups.
  • Suitable optional substituent groups include acyl (e.g. -COCH3), alkoxy (e,g, -OCH3), alkoxycarbonyl (e.g. -COOCH3), alkylamino (e.g.
  • alkylsulfinyl e.g. -SOCH3
  • alkylsulfonyl e.g. -SO CH 3
  • alkylthio e.g. -SCH3
  • -NH 2 aminoalkyl (e.g. -CH 2 NH 2 ) ? arylalkyl (e.g. -CH 2 Ph or -CH 2 -CH 2 -Ph), cyano, dialkylamino (e.g. -N(CH3) 2 ), halo, haloalkoxy (e.g. -OCF3 or -OCHF 2 ), haloalkyl (e.g.
  • alkyl e.g. -CH3 or -CH2CH3
  • alkyl e.g. -CH3 or -CH2CH3
  • -OH e.g. -CHO
  • -NO 2 aryl (optionally substituted with alkoxy, haloalkoxy, halogen, alkyl or haloalkyl), heteroaryl (optionally substituted with alkoxy, haloalkoxy, halogen, alkyl or haloalkyl), heterocycloalkyl
  • aminoacyl e.g. - CONH 2 , -CONHCH 3
  • aminosulfonyl e.g. -SO 2 NH 2 , -SO 2 NHCH 3
  • acylamino e.g.
  • -NHCOCH 3 sulfonylamino
  • sulfonylamino e.g. -NHSO 2 CH 3
  • heteroarylalkyl e.g. -NHSO 2 CH 3
  • cyclic amine e.g. morpholine
  • aryloxy, heteroaryloxy, arylalkyloxy e.g. benzyloxy
  • heteroarylalkyloxy e.g. benzyloxy
  • Compounds of the invention may exist in one or more geometrical, optical, enantiomeric, diastereomeric and tautomeric forms, including but not limited to cis- and transforms, E- and Z-forms, R-, S- and meso-forms, keto-, and enol-forms. Unless otherwise stated a reference to a particular compound includes all such isomeric forms, including racemic and other mixtures thereof. Where appropriate such isomers can be separated from their mixtures by the application or adaptation of known methods (e.g. chromatographic techniques and recrystallisation techniques). Where appropriate such isomers may be prepared by the application of adaptation of known methods (e.g. asymmetric synthesis).
  • the group A is a monocyclic heteroaryl group, preferably containing 5 or 6 ring atoms.
  • the heteroatom(s) is/are selected from N, O and S atoms, and preferably from N atom(s).
  • A is selected from monocyclic heteroaryl groups containing 5 or 6 ring atoms including one or two nitrogen heteroatoms.
  • A is selected from pyrazolyl, imidazolyl, pyridinyl and pyrimidinyl.
  • A is selected from pyrazolyl, pyridinyl and pyrimidinyl.
  • the group A may be substituted or unsubstituted, and in one embodiment, A is unsubstituted.
  • A is substituted and in this embodiment one or two substituent groups may be present.
  • the substituent groups are preferably selected from alkyl, alkoxy, haloalkyl, haloalkoxy, halogen and CN.
  • A is selected from pyrazolyl, imidazolyl, pyridinyl and pyrimidinyl optionally substituted with a substituent chosen from alkyl, alkoxy, haloalkyl, haloalkoxy, halogen and CN.
  • R 3 is selected from H and alkyl. In one embodiment, R 4 is selected from H and alkyl. In one embodiment, R 5 is selected from H and alkyl. In one embodiment, R is selected from H and alkyl. In one embodiment, R is selected from H and alkyl.
  • Q represents N and T represents CR .
  • Q represents CR 2 and T represents N.
  • Q and T both represent N.
  • n is 0, 1 or 2; in a further embodiment n is 0 or 1; and in a further embodiment n is 1.
  • m is 2 or 3.
  • m is 1 or 2.
  • m is 2.
  • p is 1 or 2, and in a further embodiment p is 1.
  • the present invention provides compounds that inhibit HDAC activity according to the tests described in the literature and in the Biological Activity section of this document.
  • the therapeutic application of these compounds is pertinent to any disease that is known to be at least in part mediated by HDAC activity or whose symptoms are known to be alleviated by HDAC inhibitors (such as Trichostatin-A, suberoyl anilide hydroxamic acid, Trapoxin and depudecin).
  • HDAC inhibitors such as Trichostatin-A, suberoyl anilide hydroxamic acid, Trapoxin and depudecin.
  • these compounds could be beneficial for the treatment of cancer, psoriasis, fibroproliferative disorders (e.g. liver f ⁇ brosis), smooth muscle cell proliferation disorders (e.g.
  • immune modulation e.g. rheumatoid arthritis, autoimmune diabetes, lup
  • the present invention is intended for the treatment of diseases caused by increased cell proliferation.
  • diseases caused by increased cell proliferation include, but are not limited to, primary and metastatic cancers of different origin (including those triggered by viral infections such as EBV, HIV, hepatitis B and C and KSHN), f ⁇ brosis of the liver, lung, kidney, heart and skin caused by myofibroblasts proliferation and increased production of extracellular matrix proteins [ ⁇ iki et al, Hepatology, 29:858-67 (1999)], inflammatory diseases and cardiomyocyte hypertrophy [Lu et al, P ⁇ AS, 97: 4070-4075 (2000)].
  • the invention is also aimed at the treatment of protozoal infections including, but not limited to, malaria, toxoplasmosis and coccidiosis.
  • the invention is aimed at the treatment of diseases caused by expanded polyglutamine repeats resulting in histone hypoacetylation including, but not limited to, neurodegenerative disorders such as Huntington's disease.
  • the compounds of formula (I) may be used or administered in combination with one or more additional drug(s) and/or procedures (such as radiotherapy in the case of cancer) useful in the treatment of the disorders mentioned above, the components being in the same formulation or in separate formulations for administration simultaneously or sequentially.
  • the additional drug(s) may or may not be HDAC inhbitors.
  • the thiazolyl-hydroxamic acids and thiadiazolyl hydroxamic acids of the present invention may be prepared, for example, by the application or adaptation of methods described herein. They may also be prepared by known organic synthesis methods for example those described by R. C. Larock in Comprehensive Organic Transformations, NCH publishers, 1989.
  • R a is a suitable protecting group.
  • Suitable protecting groups include benzyl, 'butyloxycarbonyl, dimethyrbutylsilyl, tetrahydropyranyl and Wang polystyrene resin.
  • the reactions carried out depend on the nature of the protecting group, for example if the protecting group is benzyl, the reaction carried out is a hydrogenolysis in an inert solvent such as an alcohol like methanol or ethanol, in the presence of a noble metal catalyst such as palladium on a suitable carrier such as carbon or barium sulfate, at an appropriate temperature and pressure, such as ambient temperature and pressure.
  • the protecting group is tetrahydropyranyl or Wang polystyrene resin
  • the reaction is carried out in the presence of an acid, at a temperature between -20°C and 60°C, preferably between 0°C and ambient temperature.
  • the acid may be a solution of hydrochloric acid in an inert solvent such as diethyl ether or dioxane, or trifluoroacetic acid in dichloromethane.
  • an inert solvent such as diethyl ether or dioxane
  • trifluoroacetic acid in dichloromethane.
  • the protecting group is a silyl group
  • the reaction is carried out in the presence of a fluoride source such as tetrabutylammonium fluoride in an inert solvent such as dichloromethane.
  • Compounds of formula (II) can be obtained from compounds of formula (III) by reaction with an appropriately protected hydroxylamine, such as O-(tetrahydro-2H-pyran-2- yl)hydroxylamine, O-benzylhydroxylamine, O-Wang hydroxylamine polystyrene resin or O-(dimethyl tylsilyl)hydroxylamine.
  • an appropriately protected hydroxylamine such as O-(tetrahydro-2H-pyran-2- yl)hydroxylamine, O-benzylhydroxylamine, O-Wang hydroxylamine polystyrene resin or O-(dimethyl tylsilyl)hydroxylamine.
  • reaction of compounds of formula (III) with O-(tetrahydro-2H-pyran-2-yl)hydroxylamine is conveniently carried out using an activating agent such as O-(7-azabenzotriazol-l-yl)-NNN'N'-tetramethyluronium hexafluorophosphate and a base such as diisopropylethylamine in a suitable solvent such as NN-dimethylformamide at an appropriate temperature such as ambient temperature.
  • an activating agent such as O-(7-azabenzotriazol-l-yl)-NNN'N'-tetramethyluronium hexafluorophosphate
  • a base such as diisopropylethylamine
  • a suitable solvent such as NN-dimethylformamide
  • An alternative method for the preparation of compounds of formula (I) involves the reaction of a compound of formula (III) with hydroxylamine.
  • This reaction typically involves the use of an activating agent such as O-(7-azabenzotriazol-l-yl)-NNN',N'- tetramethyluronium hexafluorophosphate ( ⁇ ATU) and a base such as diisopropylethylamine in a suitable solvent such as dimethylformamide at an appropriate temperature such as ambient temperature.
  • a compound of formula (III) can be converted to a reactive derivative, such as an acid chloride or mixed anhydride.
  • the reactive intermediate is then treated with hydroxylamine in a suitable solvent, such as dichloromethane.
  • the reactive intermediate may be used in situ without isolation, or it may be isolated and then treated with hydroxylamine.
  • Another method for the preparation of compounds of formula (I) involves the reaction of a compound of formula (IV), in which R is a suitable protecting group, such as methyl or ethyl, with hydroxylamine.
  • the reaction may be carried out in the presence of a base, such as potassium hydroxide, in a suitable solvent such as methanol.
  • a co-solvent, such as NN- dimethylacetamide may be used.
  • Compounds of formula (III) may be prepared by hydrolysis of compounds of formula (IN).
  • the hydrolysis may be carried out using a suitable base such as sodium hydroxide, in a protic solvent such as ethanol, at an appropriate temperature, such as ambient temperature.
  • the hydrolysis may be carried out under acidic conditions, for example using concentrated mineral acid, such as concentrated hydrochloric acid.
  • An alternative method for the preparation of compounds of (III) involves the hydrolysis of compounds of formula (N).
  • the hydrolysis may be carried out using a suitable base, such as sodium hydroxide, in a protic solvent such as ethanol, at an appropriate temperature, such as the reflux temperature of the solvent.
  • An additional method for the preparation of compounds of formula (III) involves the use of a compound of formula (NI), in which "hal” means chloro, bromo or iodo.
  • a compound of formula (NI) can be converted into a compound of formula (III) by any suitable method known to those skilled in the art, including the use of a palladium catalysed carbonylation reaction, or a halogen/lithium exchange followed by quenching with carbon dioxide.
  • the carbonylation reaction can be carried out using carbon monoxide in the presence of a suitable catalyst, such as bis(triphenylphosphine) palladium chloride and a suitable base, such as triethylamine in appropriate solvent(s), such as methanol and water.
  • the reaction may be carried out at any appropriate temperature and pressure, such as a temperature of HO C and a pressure of 10 bar.
  • the halogen/lithium exchange reaction may be carried out in the presence of a suitable lithium base, such as "butyl lithium, in an appropriate solvent such as tetrahydrofuran, at an appropriate temperature such as 0°C.
  • Compounds of formula (VI) may also be used to prepare compounds of fomula (IV) if the carbonylation reaction is carried out in the presence of an alcohol, such as methanol or ethanol.
  • an alcohol such as methanol or ethanol.
  • subjection of a compound of formula (VI) to halogen/lithium exchange followed by quenching with a suitable chloroformate, such as ethyl chloroformate, will also provide a compound of formula (IV).
  • Compounds of formula (V) may be prepared from compounds of formula (VI) by reaction with zinc cyanide in the presence of a palladium (0) catalyst, for example tetrakis (triphenylphospine)palladium (0), in an inert solvent, for example NN- dimethylformamide, at temperatures from about room temperature up to reflux temperature.
  • a palladium (0) catalyst for example tetrakis (triphenylphospine)palladium (0)
  • an inert solvent for example NN- dimethylformamide
  • Compounds of formula (VI) may be prepared from compounds of formula (VII) by reaction with an appropriate halogenating agent, such as bromine, iodine, N- chlorosuccinimide, N-bromosuccinimide, or N-iodosuccinimide, in an appropriate solvent, such as dichloromethane.
  • an appropriate halogenating agent such as bromine, iodine, N- chlorosuccinimide, N-bromosuccinimide, or N-iodosuccinimide
  • Compounds of formula (IV) may be prepared from compounds of formula (VIII), in which R c represents hydrogen, lower alkyl, or -B(OR c ) 2 represents a cyclic boronate ester, and a compound of formula (IX), in which "hal" and R b are as previously defined.
  • the reaction may be performed in the presence of a suitable catalyst, such as tetrakis(triphenylphosphine)palladium (0), and a suitable base, such as cesium carbonate, in an appropriate solvent such as NN-dimethylformamide, at a suitable temperature, such as an elevated temperature, such as 80°C.
  • a suitable catalyst such as tetrakis(triphenylphosphine)palladium (0)
  • a suitable base such as cesium carbonate
  • an appropriate solvent such as NN-dimethylformamide
  • compounds of formula (III) may be prepared from compounds of formula (VIII) and a compound of formula (X), and compounds of formula (V) can be prepared starting from compounds of formula (XI).
  • An alternative method for the preparation of compounds of formula (IV) involves the reaction of a compound of formula (XII), in which hal is as previously defined, with a compound of formula (XIII) in which R and R c are as previously defined.
  • the reaction may be performed in the presence of a suitable catalyst, such as tetrakis(triphenylphosphine)palladium (0), and a suitable base, such as cesium carbonate, in an appropriate solvent such as NN-dimethylformamide, at a suitable temperature, such as an elevated temperature, such as 80°C.
  • compounds of formula (III) may be prepared from compounds of formula (XII) and a compound of formula (XIV), and compounds of formula (V) can be prepared starting from compounds of formula (XV).
  • Compounds of formula (XIII), (XIV) and (XV) may be commercially available, or may be prepared from compounds of formula (IX), (X) or (XI) respectively by conversion to a suitable organometallic reagent, such as a lithium or magnesium reagent and subsequent treatment with a suitable boron reagent, such as trimethylborate.
  • a suitable organometallic reagent such as a lithium or magnesium reagent
  • boron reagent such as trimethylborate
  • compounds of formula (IX), (X) or (XI) may be treated with a suitable boron reagent, such as bis(pinacolato)diboron, in the presence of a suitable catalyst, such as [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium, and a suitable base, such as potassium acetate, in an appropriate solvent, such as dioxane, at a suitable temperature, for example room temperature to the reflux temperature of the solvent.
  • a suitable boron reagent such as bis(pinacolato)diboron
  • a suitable catalyst such as [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium
  • a suitable base such as potassium acetate
  • Compounds of formula (NIII) may be prepared from compounds of formula (XII) using the procedures described above for the conversion of compounds of formula (IX), (X) or (XI) into compounds of formula (XIII), (XIV) and (XV).
  • Compounds of formula (XII) may be prepared using any suitable procedure known to those skilled in the art, including standard functional group interconversions.
  • primary amine (-NH 2 ) groups may be alkylated using a reductive aU ylation process employing an aldehyde or a ketone and a borohydride, for example sodium triacetoxyborohydride or sodium cyanoborohydride, in a solvent such as a hal ⁇ genated hydrocarbon, for example 1,2-dichloroethane, or an alcohol such as ethanol, where necessary in the presence of an acid such as acetic acid at around ambient temperature.
  • Secondary amine (-NH-) groups may be similarly alkylated employing an aldehyde.
  • primary amine or secondary amine groups may be converted into amide groups (-NHCOR' or -NRCOR') by acylation.
  • Acylation may be achieved by reaction with an appropriate acid chloride in the presence of a base, such as triethylamine, in a suitable solvent, such as dichloromethane, or by reaction with an appropriate carboxylic acid in the presence of a suitable coupling agent such HATU (O-(7- azabenzotriazol-l-y ⁇ -NNN ⁇ N'-tetramethyluronium hexafluorophosphate) in a suitable solvent such as dichloromethane.
  • HATU O-(7- azabenzotriazol-l-y ⁇ -NNN ⁇ N'-tetramethyluronium hexafluorophosphate
  • amine groups may be converted into sulphonamide groups (- ⁇ HSO 2 R' or -NR"SO R') groups by reaction with an appropriate sulphonyl chloride in the presence of a suitable base, such as triethylamine, in a suitable solvent such as dichloromethane.
  • Primary or secondary amine groups can be converted into urea groups (-NHCONR'R" or -NRCONR'R”) by reaction with an appropriate isocyanate in the presence of a suitable base such as triethylamine, in a suitable solvent, such as dichloromethane.
  • An amine (-NH 2 ) may be obtained by reduction of a nitro (-NO 2 ) group, for example by catalytic hydrogenation, using for example hydrogen in the presence of a metal catalyst, for example palladium on a support such as carbon in a solvent such as ethyl acetate or an alcohol e.g. methanol.
  • a metal catalyst for example palladium on a support such as carbon in a solvent such as ethyl acetate or an alcohol e.g. methanol.
  • the transformation may be carried out by cjhemical reduction using for example a metal, e.g. tin or iron, in the presence of an acid such as hydrochloric acid.
  • amine (-CH 2 NH 2 ) groups may be obtained by reduction of nitriles (- CN), for example by catalytic hydrogenation using for example hydrogen in the presence of a metal catalyst, for example palladium on a support such as carbon, or Raney nickel, in a solvent such as an ether e.g. a cyclic ether such as tetrahydrofuran, at a temperature from -78°C to the reflux temperature of the solvent.
  • a metal catalyst for example palladium on a support such as carbon, or Raney nickel
  • Aldehyde groups may be converted to amine groups (-CH 2 NR'R")) by -reductive amination employing an amine and a borohydride, for example sodium triacetoxyborohydride or sodium cyanoborohydride, in a solvent such as a halogenated hydrocarbon, for example dichloromethane, or an alcohol such as ethanol, where necessary in the presence of an acid such as acetic acid at around ambient temperature.
  • a borohydride for example sodium triacetoxyborohydride or sodium cyanoborohydride
  • a solvent such as a halogenated hydrocarbon, for example dichloromethane, or an alcohol such as ethanol
  • Aldehyde groups may be obtained by reduction of ester groups (such as -CO 2 Et) or nitr ⁇ les (-CN) using diisobutylaluminium hydride in a suitable solvent such as toluene.
  • ester groups such as -CO 2 Et
  • -CN nitr ⁇ les
  • aldehyde groups may be obtained by the oxidation of alcohol groups using any suitable oxidising agent known to those skilled in the art.
  • Ester groups (-CO 2 R') may be converted into the corresponding acid group (-CO 2 H) by acid- or base-catalused hydrolysis, depending on the nature of R. If R is t-butyl, acid- catalysed hydrolysis can be achieved for example by treatment with an organic acid such as trifiuoroacetic acid in an aqueous solvent, or by treatment with an inorganic acid such as hydrochloric acid in an aqueous solvent.
  • Carboxylic acid groups may be converted into amides (-CONHR' or -CONR'R”) by reaction with an appropriate amine in the presence of a suitable coupling agent, such as HATU, in a suitable solvent such as dichloromethane.
  • a suitable coupling agent such as HATU
  • carboxylic acids may be homologated by one carbon (i.e -CO 2 H to - CH 2 CO 2 H) by conversion to the conesponding acid chloride (-COC1) followed by Arndt- Eistert synthesis.
  • -OH groups may be generated from the conesponding ester (e.g. - CO 2 R'), or aldehyde (-CHO) by reduction, using for example a complex metal hydride such as lithium aluminium hydride in diethyl ether or " tetrahydrofuran, or sodium borohydride in a solvent such as methanol.
  • an alcohol may be prepared by reduction of the conesponding acid (-CO 2 H), using for example lithium aluminium hydride in a solvent such as tetrahydrofuran, or by using borane in a solvent such as tetrahydrofuran.
  • Alcohol groups may be converted into leaving groups, such as halogen atoms or sulfonyloxy groups such as an alkylsulfonyloxy, e.g. trifluoromethylsulfonyloxy or arylsulfonyloxy, e.g. j ⁇ -toluenesulfonyloxy group using conditions known to those skilled in the art.
  • halogen atoms or sulfonyloxy groups such as an alkylsulfonyloxy, e.g. trifluoromethylsulfonyloxy or arylsulfonyloxy, e.g. j ⁇ -toluenesulfonyloxy group using conditions known to those skilled in the art.
  • an alcohol may be reacted with thionyl chloride in a halogenated hydrocarbon (e.g. dichloromethane) to yield the conesponding chloride.
  • a base e.g. trieth
  • alcohol or phenol groups may be converted to ether groups by coupling a phenol with an alcohol in a solvent such as tetrahydrofuran in the presence of a phosphine, e.g. triphenylphosphine and an activator such as diethyl-, diisopropyl, or dimethylazodicarboxylate.
  • a phosphine e.g. triphenylphosphine
  • an activator such as diethyl-, diisopropyl, or dimethylazodicarboxylate.
  • ether groups may be prepared by deprotonation of an alcohol, using a suitable base e.g. sodium hydride followed by subsequent addition of an alkylating agent, such as an alkyl halide.
  • Aromatic halogen substituents in the compounds may be subjected to halogen-metal exchange by treatment with a base, for example a lithium base such as "butyl or 'butyl lithium, optionally at a low temperature, e.g. around -78°C, in a solvent such as tetrahydrofuran, and then quenched with an electrophile to introduce a desired substituent.
  • a base for example a lithium base such as "butyl or 'butyl lithium
  • a solvent such as tetrahydrofuran
  • an electrophile to introduce a desired substituent.
  • a formyl group may be introduced by using NN-dimethylformamide as the electrophile.
  • Aromatic halogen substituents may alternatively be subjected to metal (e.g.
  • compounds of formula (I) in which A is heteroaryl containing an N-oxide group may be prepared by oxidation of compounds of formula (I) in which A is the conesponding non-oxidised he ⁇ teroaryl.
  • compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers or " excipients.
  • the active compounds of the invention may be formulated for oral, buccal, intranasal, parenteral (e.g. intravenous, intramuscular or subcutaneous) transdermal or rectal administration or in a form suitable for administration by inhalation or insufflation.
  • the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpynolidone or hydroxypropylmethylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); or wetting agents (e.g. sodium lauryl sulphate).
  • binding agents e.g. pregelatinised maize starch, polyvinylpynolidone or hydroxypropylmethylcellulose
  • fillers e.g. lactose, microcrystalline cellulose or calcium phosphate
  • lubricants e.g. magnesium stearate, talc or silica
  • disintegrants e.g. potato starch or sodium starch glycollate
  • Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters or ethyl alcohol); and preservatives (e.g. methyl or propyl p-hydroxybenzoates or sorbic acid).
  • suspending agents e.g. sorbitol syrup, methyl cellulose or hydrogenated edible fats
  • emulsifying agents e.g. lecithin or acacia
  • non-aqueous vehicles e.g. almond oil, oily esters or ethyl alcohol
  • preservatives e.g
  • composition may take the form of tablets or lozenges formulated in conventional manner.
  • the active compounds of the invention may be formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion.
  • Formulations for injection may be presented in unit dosage form (e.g. in ampoules or in multi-dose containers, with an added preservative).
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilising and/or dispersing agents.
  • the active ingredient may be in powder form for reconstitution with a suitable vehicle, (e.g. sterile pyrogen-free water), before use.
  • the active compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, (e.g. containing conventional suppository bases such as cocoa butter or other glycerides).
  • rectal compositions such as suppositories or retention enemas, (e.g. containing conventional suppository bases such as cocoa butter or other glycerides).
  • the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, (e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas).
  • a suitable propellant e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • the pressurized container or nebulizer may contain a solution or suspension of the active compound.
  • Capsules and cartridges for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
  • a proposed dose of the active compounds of the invention for oral, parenteral or buccal administration to the average adult human for the treatment of the conditions refened to above is 0.1 to 500 mg of the active ingredient per unit dose which could be administered, for example, 1 to 4 times per day.
  • Method A Experiments performed on a Finnigan TSQ700 spectrometer with positive ion electrospray and single wavelength UV 254 nm detection using a Higgins Clipeus C18 5 ⁇ m 100 x 3.0 mm column and a 2 ml / minute flow rate.
  • the initial solvent system was 95% water containing 0.1% formic acid (solvent A) and 5% acetonitrile containing 0.1% formic acid (solvent B) for the first minute followed by a gradient up to 5% solvent A and 95% solvent B over the next 14 minutes. The final solvent system was held constant for a further 2 minutes.
  • Reverse-phase High Pressure Liquid Chromatography (HPLC) purification was performed using a Genesis HPLC Column (Ref. 16R10985, 100 mm x 22.5 mm) containing C18-7 ⁇ m 120 A silica, eluting with a gradient of acetonitrile (containing 0.1% trifluoroacetic acid) in water (containing 0.1% trifluoroacetic acid) at a flow rate of 5 ml/min.
  • the starting gradient was 10% acetonitrile, and was increased at a rate of 1% per minute up to 50% acetonitrile/water unless otherwise stated.
  • UV detection at 230 nm used unless otherwise stated.
  • Microwave experiments were carried out using a Personal Chemistry Smith SynthesizerTM, which uses a single-mode resonator and dynamic field tuning, both of which give reproducibility and control. Temperature from 40-250 °C can be achieved, and pressures of up to 20 bar can be reached. Two types of vial are available for this processor; 0.5-2.0 mL and 2.0-5.0 mL.
  • the salt was then dissolved in DMF (3 mL) and treated with O-(tetrahydro-pyran-2-y ⁇ )- hydroxylamine (Aldrich; 34 mg, 0.29 mmol), O-(7-azabenzotriazol-l-yl)-N,N,N',N'- tetramethyluoronium hexafluorophosphate (Aldrich; 143 mg, 0.38 mmol) and then diisopropylethylamine (130 ⁇ L, 0.75 mmol). The resulting mixture was stined at room temperature for 45 minutes then concentrated in vacuo.
  • a microwave vial (20 mL) was charged with a solution, in DMF (20 mL), of 2- tributylstannanyl-pyridine (Aldrich; 80%, 2.19g, 4.76 mmol), 2,5-dibromo-thiazole (Aldrich; 2.0 g, 8.23 mmol) and dichlorobis(triphenylphosphine)palladium(II) (395 mg, 0.56 mmol).
  • the resulting mixture was microwave inadiated for 3 minutes at 140 °C then diluted with methanol (20 mL) and applied to an SCX-2 cartridge (70 g; sulphonic acid ion-exchange resin).
  • the crude amine intermediate was dissolved in dichloromethane (4 mL) and treated with diisopropylethylamine (0.43 mL, 2.48 mmol) followed by a solution, in dichloromethane (0.5 mL), of di-tert-butyl dicarbonate (270 mg, 1.24 mmol).
  • reaction mixture was heated to reflux for 18 hours then cooled and partitioned between aqueous saturated ammonium chloride (250 mL) and dichloromethane (3 x 150 mL). The combined dichloromethane extracts were dried (Na 2 SO ),"f ⁇ ltred then concentrated in vacuo.
  • the crude product was purified by flash chromatography on silica-gel, loading in dichloromethane and gradient eluting from 5% ethyl acetate/petrol (40-60 °C) to 20% ethyl acetate/petrol (40-60 °C) to give 2-(5-[1.3]dioxolan-2-yl-pyridin-2-ylVthiazole-5- carboxylic acid methyl ester (700 mg, 21%) as a yellow solid.
  • the aqueous layer was extracted with ethyl acetate (3 x 25 mL) and the combined organic extracts washed with water (25 mL) and brine (25 ml) then dried (Na 2 SO ), prior to filtering and concentration in vacuo.
  • the crude product was purified by flash chromatography on silica-gel, gradient eluting from 20% ethyl acetate hexane to 20% ethyl acetate/hexane to give 2-(l-trityl-lH-imidazol-4-ylVthiazole-5-carboxylic methyl ester
  • the title compound was prepared from 4-iodo-l-trityl-lH-imidazole (Combi Blocks) using the procedure detailed in Synthesis 1998, 6, 829.
  • Compounds are tested for their capacity to inhibit histone deacetylase activity (primary assay) and for their biological effects on growing cells (secondary assay).
  • Total lysates from K562 chronic human myelogenous leukemia cells (obtained from American Type Culture Collection, Rockville, MD) are used as source of HDAC activity.
  • Cells are grown in RPMI media supplied with 10% FCS, harvested by centrifugation, washed once in PBS and resuspended at a density of 24xl ⁇ 6/ml in HDA buffer (15mM Potassium phosphate pH 7.5, 5% glycerol, 0.2mM EDTA). After sonication, lysates are centrifuged at lOOOg for 20 minutes and the resulting supernatant is aliquoted and stored at -80°C.
  • BIOMOL commercially available HeLa nuclear extracts
  • the assay was canied out for 30 minutes using 116 ⁇ M of a fluorescent substrate containing an acetylated lysine residue (BIOMOL).
  • a fluorescent substrate containing an acetylated lysine residue (BIOMOL).
  • the substrate can react with the added developer producing a fluorophore.
  • the amount of fluorophore produced is proportional to the HDAC activity in the sample and is quantified using a multiwell fluonmeter capable of excitation at 360nm and detection at 450nm.
  • Compounds are diluted in DMSO prior to addition to assay buffer, the final DMSO concentration in the assay being 1%.
  • % activity ⁇ (F s - B) / (F c - B) ⁇ x 100
  • F s is the fluorescence at 450nm in the presence of the tested compound (Sample).
  • F c is the fluorescence at 450nm in the presence of vehicle 1 % DMSO (Control).
  • B is the fluorescence at 450nm in the absence of enzyme (Background fluorescence)
  • the IC 50 is defined as the concentration at which a given compound achieves 50% activity.
  • IC5 0 values are calculated using the XLfit sof ware package (version 2.0.5).
  • MCF-7 are kept in MEM medium (Gibco) supplemented with 10% FCS and 1% Non Essential Amino Acids at 37°C in a 5% CO humidified incubator.
  • MDA-MB-231 are kept in L-15 (Leibovitz) medium (Gibco) supplemented with 15% FCS at 37°C in a non-modified atmosphere, humidified incubator.
  • Cells are seeded in 96-well plates at a density of 20,000 cells/ml (3,000 cells/well) and after 24h they are exposed to different concentrations of compounds in 0.1% DMSO.
  • Cells are grown for a further 72h, the media is removed and the cells are frozen at -80°C for at least 30 minutes and lysed in a solution containing the CyQUANT dye.
  • This is a fluorescent molecule that specifically binds nucleic acids and whose fluorescence is greatly enhanced upon binding nucleic acids. Therefore the fluorescence intensity is proportional to the number of cells present in each well and can be quantified using a multiwell fmorimeter by measuring the fluorescence of the solution at 520nm.
  • % activity ⁇ (A s - B) / (A c - B) ⁇ x 100
  • a s is the fluorescence at 520nm in the presence of the tested compound (Sample).
  • a c is the fluorescence at 520nm in the presence of vehicle 0.1% DMSO (Control).
  • B is the fluorescence at 520nm in the absence of cells (Background fluorescence).
  • the IC 50 is defined as the concentration at which a given compound achieves 50% activity. IC 50 values are calculated using the XLfit software package (version 2.0.5).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un composé de la formule (I) dans laquelle A représente hétéroaryle ou phényle monocyclique facultativement substitué; B représente hétéroaryle facultativement substitué, aryle, hétérocycloalkyle fusionné à aryle, cycloalkyle fusionné à hétéroaryle, hétérocycloalkyle fusionné à hétéroaryle ou cycloalkyle fusionné à aryle, ou B représente H lorsque L représente une liaison simple; L représente une liaison simple, alkylène, (CH2)nX(CH2)m, (CH2)nX(CH2)pY(CH2)m; Q représente N ou CR2; T représente N ou CR2, à condition que Q et T ne représentent pas tous les deux CR2 simultanément; X représente -O-, -NR3-, -CO-, -SO2-, -NR3CO-, -NR3SO2-, -CONR3-, -SO2NR3-, -NR1CONR1-; Y représente -NR3- ou -O-; R1 représente H ou alkyle; R2 représente hydrogène, halogène, alkyle, haloalkyle, alcoxy, haloalcoxy, CN; R3 représente H, alkyle, arylalkyle, hétéroarylalkyle, hétérocycloalkylealkyle, cycloalkylealkyle, ou alkyle substitué par -OR4, -NR5R6, -NR6COR7, -NR6SO2R7, -CONR5R6 ou -SO2NR5R6; R4 représente H, alkyle, arylalkyle, hétéroarylalkyle, hétérocycloalkylalkyle, cycloalkylalkyle, aryle, hétéroaryle, hétérocycloalkyle ou cycloalkyle; R5 représente H ou alkyle; R6 représente H, alkyle, arylalkyle, hétéroarylalkyle, hétérocycloalkylalkyle, cycloalkylalkyle, aryle, hétéroaryle, hétérocycloalkyle ou cycloalkyle ou NR5R6 représente une amine cyclique; R7 représente alkyle, aryle, hétéroaryle, cycloalkyle, hétérocycloalkyle, aryllkyle, hétéroarylalkyle, cycloalkylalkyle ou hétérocycloalkylalkyle; n représente 0-3; m représente 0-3; p représente 1-3; ainsi que les N-oxydes correspondants, ces sels, solvates et promédicaments pharmaceutiquement acceptables; ainsi que l'utilisation dudit composé pour traiter une maladie dans laquelle l'inhibition de l'histone déacétylase peut prévenir, inhiber ou améliorer l'état pathologique et/ou symptomatologique de la maladie.
PCT/GB2005/000282 2004-02-04 2005-01-27 Acides thiazolyl-hydroxamiques, acides thiadiazolyl-hydroxamiques et leur utilisation pour traiter des maladies associees a une activite enzymatique histone deacetylase WO2005075469A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0402496.4A GB0402496D0 (en) 2004-02-04 2004-02-04 Novel compounds
GB0402496.4 2004-02-04

Publications (1)

Publication Number Publication Date
WO2005075469A1 true WO2005075469A1 (fr) 2005-08-18

Family

ID=31985669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/000282 WO2005075469A1 (fr) 2004-02-04 2005-01-27 Acides thiazolyl-hydroxamiques, acides thiadiazolyl-hydroxamiques et leur utilisation pour traiter des maladies associees a une activite enzymatique histone deacetylase

Country Status (2)

Country Link
GB (1) GB0402496D0 (fr)
WO (1) WO2005075469A1 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028999A1 (fr) * 2005-09-09 2007-03-15 Argenta Discovery Limited Composés de thiazole et leur utilisation en tant qu'antagonistes de pgd2
JP2009526830A (ja) * 2006-02-15 2009-07-23 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ヒストン脱アセチル化酵素（ｈｄａｃ）阻害剤としてのチオフェン及びチアゾール置換トリフルオロエタノン誘導体
US7834025B2 (en) 2006-01-19 2010-11-16 Janssen Pharmaceutica N.V. Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
US7834011B2 (en) 2006-01-19 2010-11-16 Janssen Pharmaceutica N.V. Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase
US7888360B2 (en) 2006-01-19 2011-02-15 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US8071615B2 (en) 2002-03-13 2011-12-06 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
US8101616B2 (en) 2006-01-19 2012-01-24 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US8114999B2 (en) 2002-03-13 2012-02-14 Janssen Pharmaceutica N.V. Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
US8114876B2 (en) 2006-01-19 2012-02-14 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US8119650B2 (en) 2006-01-19 2012-02-21 Janssen Pharmaceutica N.V. Aminophenyl derivatives as novel inhibitors of histone deacetylase
US8138198B2 (en) 2005-05-18 2012-03-20 Angibaud Patrick Rene Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
US8163733B2 (en) 2002-03-13 2012-04-24 Janssen Pharmaceutica N.V. Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
US8193205B2 (en) 2004-07-28 2012-06-05 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
US8236835B2 (en) 2006-09-22 2012-08-07 Novartis Ag Heterocyclic inhibitors of stearoyl-CoA desaturase
US8258160B2 (en) 2006-12-20 2012-09-04 Novartis Ag SCD1 inhibitors triazole and tetrazole compounds
US8314138B2 (en) 2006-08-24 2012-11-20 Novartis Ag Pyrazole derivative as SCD1 inhibitors for the treatment of diabetes
US8501737B2 (en) 2002-03-13 2013-08-06 Janssen Pharmaceutica N.V. Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
WO2015192078A1 (fr) * 2014-06-12 2015-12-17 Cedars-Sinai Medical Center Compositions et procédés de traitement de cancers
EP3769757A3 (fr) * 2013-10-18 2021-10-06 The General Hospital Corporation Imagerie d'histone désacétylases au moyen d'un radiotraceur à l'aide de la tomographie par émission de positrons

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038322A1 (fr) * 1999-11-23 2001-05-31 Methylgene, Inc. Inhibiteurs de l'histone deacetylase
WO2005040161A1 (fr) * 2003-10-27 2005-05-06 S*Bio Pte Ltd Hydroxamates lies au biaryle: preparation et applications pharmaceutiques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038322A1 (fr) * 1999-11-23 2001-05-31 Methylgene, Inc. Inhibiteurs de l'histone deacetylase
WO2005040161A1 (fr) * 2003-10-27 2005-05-06 S*Bio Pte Ltd Hydroxamates lies au biaryle: preparation et applications pharmaceutiques

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9533979B2 (en) 2002-03-13 2017-01-03 Janssen Pharmaceutica Nv Amino-derivatives as novel inhibitors of histone deacetylase
US8114999B2 (en) 2002-03-13 2012-02-14 Janssen Pharmaceutica N.V. Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
US9556161B2 (en) 2002-03-13 2017-01-31 Janssen Pharmaceutica Nv Inhibitors of histone deacetylase
US8501737B2 (en) 2002-03-13 2013-08-06 Janssen Pharmaceutica N.V. Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
US9150560B2 (en) 2002-03-13 2015-10-06 Janssen Pharmaceutica Nv Inhibitors of histone deacetylase
US8916554B2 (en) 2002-03-13 2014-12-23 Janssen Pharmaceutica, N.V. Amino-derivatives as novel inhibitors of histone deacetylase
US8071615B2 (en) 2002-03-13 2011-12-06 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
US8524711B2 (en) 2002-03-13 2013-09-03 Janssen Pharmaceutica N.V. Amino-derivatives as novel inhibitors of histone deacetylase
US8455498B2 (en) 2002-03-13 2013-06-04 Janssen Pharmaceutica N.V. Inhibitors of histone deacetylase
US8343988B2 (en) 2002-03-13 2013-01-01 Janssen Pharmaceutica, N.V Inhibitors of histone deacetylase
US8268833B2 (en) 2002-03-13 2012-09-18 Janssen Pharmaceutica, N.V. Inhibitors of histone deacetylase
US8163733B2 (en) 2002-03-13 2012-04-24 Janssen Pharmaceutica N.V. Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
US8592441B2 (en) 2004-07-28 2013-11-26 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
US9636341B2 (en) 2004-07-28 2017-05-02 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
US9150543B2 (en) 2004-07-28 2015-10-06 Janssen Pharmaceutica N. V. Substituted indolyl alkyl amino derivatives as inhibitors of histone deacetylase
US8193205B2 (en) 2004-07-28 2012-06-05 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
US8138198B2 (en) 2005-05-18 2012-03-20 Angibaud Patrick Rene Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
WO2007028999A1 (fr) * 2005-09-09 2007-03-15 Argenta Discovery Limited Composés de thiazole et leur utilisation en tant qu'antagonistes de pgd2
US8114876B2 (en) 2006-01-19 2012-02-14 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US7888360B2 (en) 2006-01-19 2011-02-15 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US7834011B2 (en) 2006-01-19 2010-11-16 Janssen Pharmaceutica N.V. Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase
US9078896B2 (en) 2006-01-19 2015-07-14 Janssen Pharmaceutica, N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US8101616B2 (en) 2006-01-19 2012-01-24 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US8664223B2 (en) 2006-01-19 2014-03-04 Janssen Pharmaceutica N.V Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US8119650B2 (en) 2006-01-19 2012-02-21 Janssen Pharmaceutica N.V. Aminophenyl derivatives as novel inhibitors of histone deacetylase
US7834025B2 (en) 2006-01-19 2010-11-16 Janssen Pharmaceutica N.V. Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
US8163765B2 (en) 2006-01-19 2012-04-24 Janssen Pharmaceutica N.V. Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
JP2015110584A (ja) * 2006-02-15 2015-06-18 エンメエッセディ・イタリア・エッセ・エッレ・エッレ ヒストン脱アセチル化酵素（ｈｄａｃ）阻害剤としてのチオフェン及びチアゾール置換トリフルオロエタノン誘導体
JP2009526830A (ja) * 2006-02-15 2009-07-23 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ヒストン脱アセチル化酵素（ｈｄａｃ）阻害剤としてのチオフェン及びチアゾール置換トリフルオロエタノン誘導体
US8314138B2 (en) 2006-08-24 2012-11-20 Novartis Ag Pyrazole derivative as SCD1 inhibitors for the treatment of diabetes
US8236835B2 (en) 2006-09-22 2012-08-07 Novartis Ag Heterocyclic inhibitors of stearoyl-CoA desaturase
US8258160B2 (en) 2006-12-20 2012-09-04 Novartis Ag SCD1 inhibitors triazole and tetrazole compounds
EP3769757A3 (fr) * 2013-10-18 2021-10-06 The General Hospital Corporation Imagerie d'histone désacétylases au moyen d'un radiotraceur à l'aide de la tomographie par émission de positrons
WO2015192078A1 (fr) * 2014-06-12 2015-12-17 Cedars-Sinai Medical Center Compositions et procédés de traitement de cancers
US10029997B2 (en) 2014-06-12 2018-07-24 Cedars-Sinai Medical Center Compositions and methods for treating cancers
US10266505B2 (en) 2014-06-12 2019-04-23 Cedars-Sinai Medical Center Compositions and methods for treating cancers
US10836735B2 (en) 2014-06-12 2020-11-17 Cedars-Sinai Medical Center Compositions and methods for treating cancers
AU2015274334B2 (en) * 2014-06-12 2020-12-17 Cedars-Sinai Medical Center Compositions and methods for treating cancers
JP2017523141A (ja) * 2014-06-12 2017-08-17 シーダーズ−サイナイ メディカル センター がん治療のための組成物及び方法
AU2021201667B2 (en) * 2014-06-12 2022-11-17 Cedars-Sinai Medical Center Compositions and methods for treating cancers
EP4306173A3 (fr) * 2014-06-12 2024-04-10 Cedars-Sinai Medical Center Compositions et méthodes de traitement de cancers

Also Published As

Publication number Publication date
GB0402496D0 (en) 2004-03-10

Similar Documents

Publication Publication Date Title
WO2005075469A1 (fr) Acides thiazolyl-hydroxamiques, acides thiadiazolyl-hydroxamiques et leur utilisation pour traiter des maladies associees a une activite enzymatique histone deacetylase
CA2947283C (fr) Inhibiteurs de la demethylase-1 specifiques de la lysine
US10626104B2 (en) Inhibitors of lysine specific demethylase-1
MXPA05001334A (es) Acidos tienil-hidroxamicos sustituidos como inhibidores de la desacetilasa de histona.
EP1960390B1 (fr) Dérivés de biaryle pouvant être employés en tant qu'agonistes du récepteur gpr38
KR20030081173A (ko) α,β-불포화 하이드록사믹 액시드 유도체와 이 화합물의히스톤 디아세틸라제 억제제로서의 용도
EP3431471A1 (fr) Composé de cyclopropylamine fluorée, procédé de préparation de ce dernier, composition pharmaceutique basée sur ce dernier, et utilisations de ce dernier
CN111747948A (zh) 组蛋白脱乙酰酶抑制剂
CN114340740A (zh) β肾上腺素能激动剂及其使用方法
JP2013516480A (ja) ヘッジホッグ阻害剤
AU2004207657A1 (en) Aryl alkyl carbamate derivatives production and use thereof in therapy
IL264718B2 (en) Treatment of solid tumors and non-Hodgkin's lymphomas that have relapsed and/or are resistant
WO2005014588A1 (fr) Acides hydroxamiques de thienyle substitues presentant une activite de deacetylase
WO2010031708A2 (fr) Nouveaux ortho-aminoanilides pour le traitement du cancer
WO2005075466A1 (fr) Thienyl-mercaptoketones substitues, et utilisation associee pour le traitement de maladies liees a l'activite enzymatique d'histone deacetylase
JP2003523992A (ja) 新規フェニルヘテロアリールアルキルアミン誘導体
EP1615629B1 (fr) Inhibiteurs de la peptide deformylase
KR100553593B1 (ko) 히스톤 디아세틸라제 저해활성을 갖는 벤즈히드록시아미드유도체 및 그의 제조방법
EP4171569A1 (fr) Dérivés de quinazolinones pour le traitement de la stéatose hépatique non alcoolique, leur préparation et leur utilisation
CN117551078A (zh) 芳香单环类衍生物及其制备方法和用途
NZ725914B2 (en) Inhibitors of lysine specific demethylase-1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)